PREVALENCE OVERACTIVE BLADDER AT TERTIARY HOSPITAL : A RETROSPECTIVE SINGLE CENTER STUDY
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: Overactive bladder (OAB) is a chronic medical condition that has a tremendous impact on the quality of life for both men and women. Urgency is a primary symptom in diagnosing OAB and is closely related to the urge to urinate frequently during the day. Material & Methods : A retrospective study was conducted from January 2018 until December 2020 by using medical records database in our institution. There were 562 patients. Inclusion criteria used in this study are patients with OAB symptoms with any etiology who have undergone conservative, moderate, or future or postoperative measures in the study period. The patient who cannot be cooperative in filling out the International Prostate Symptom Score (IPSS) questionnaire or the patient who refuses were excluded from this study. Statistical analysis was performed using Pearson correlation and linear regression. Results: From the results, linear regression, obtained significance (p <0.05) on the variables of frequency, urgency and nocturia. A linear regression value of y= -0.005 + 0.987X was obtained which illustrates that the higher the frequency, urgency and nocturia variables, the higher the possibility of Lower urinary tract symptoms (LUTS) that can be correlated with OAB. Conclusion: Frequency, nocturia, and urgency are factors that influence the significance of the IPSS variable on the total IPSS score. Questionnaire items on overactive bladder symptoms score (OABSS) have a significant correlation with IPSS scores.
##plugins.themes.bootstrap3.article.details##
Overactive bladder, IPSS, OABSS, LUTS
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29: 4–20.
Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ, Michel MC. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 2010; 105: 1141–1146.
de Boer TA, Slieker-ten Hove MC, Burger CW, Vierhout ME. The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J. 2011; 22(5): 569–575.
Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012; 188(6 Suppl): 2455–63.
Kessler TM, Burkhard FC, Z’Brun S et al. Effect of thalamic deep brain stimulation on lower urinary tract function. Eur Urol 2008; 53: 607–12.
Shim SB, Kim JH, Choi H, Bae JH, Kim HJ, Kwon SS, et al. Association between self-perception period of lower urinary tract symptoms and International Prostate Symptom Score: a propensity score matching study. BMC Urology. 2015; 15(30)
Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of Overactive Bladder. Lower urinary tract symptoms. 2012; 4 Suppl 1: 48–55.
Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. International urogynecology journal and pelvic floor dysfunction. 208; 19(10): 1353–1357.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Cornu JN. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. European urology. 2019; 75(6): 988-1000.
Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacology & Therapeutics. 2018; 189: 130-148.
Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. In Mayo Clinic Proceedings. 2020; 95(2): 370-377.
Robinson D, Cardozo L. Managing overactive bladder. Climacteric. 2019; 22(3): 250-256.
De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, Madersbacher S. Beyond antimuscarinics: a review of pharmacological and interventional options for overactive bladder management in men. European urology. 2021; 79(4): 492-504.
Harrina, Budi, Surahman, Benny, Tjahjodjati, Fernandi, et all. Panduan Tata Laksana Inkontinensia Urine pada Dewasa. Jakarta. IAUI. 2018.
Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. International urogynecology journal. 2019; 30(10): 1603-1617.
Zhu J, Hu X, Dong X, Li L. Associations between risk factors and overactive bladder: a meta-analysis. Female pelvic medicine & reconstructive surgery. 2019; 25(3): 238.